Biogen multiple sclerosis drug Tecfidera wins European approval

Your Health Matters

A pedestrian passes the sign outside the headquarters of Biogen Idec Inc. in CambridgeBiogen Idec Inc's high profile new multiple sclerosis drug Tecfidera won European approval, the company said on Monday, opening the door for its launch in one of the world's largest markets for MS treatments. The approval was widely expected after the European Medicines Agency endorsed the drug in November. Tecfidera will be the third oral MS drug available in Europe. The introduction in Europe will start in the coming weeks, although its full roll-out will take place over the course of this year and next as Biogen must negotiate reimbursement for the treatment on a country by country basis.

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave